Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System (PERFUSE)
Pulmonary Embolism Removal With the AngioJet 6F Ultra SystEm (PERFUSE)
Sponsor: Boston Scientific Corporation
Terminated
Slow Enrollment
Other terminated trials from Boston Scientific Corporation
- Atrial Fibrillation Paroxysmal · Phase NA · Nov 2025
- Benign Prostatic Hyperplasia · Phase NA · Jul 2025
- Varicose Veins · Phase PHASE4 · Apr 2024
- Benign Biliary Strictures With Current or Prior Biliary Obstruction · Phase PHASE4 · Feb 2024
- Heart Failure NYHA Class II · Oct 2023
More terminations from Boston Scientific Corporation
Other Pulmonary Embolism trials with similar outcome
This PHASE4 trial investigates Pulmonary Embolism and is currently terminated or withdrawn. Boston Scientific Corporation leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .